Drug intelligence / Profile preview

FA-ORMD

Development stage: Preclinical
Lead developer: Weill Cornell Medicine
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

FA-ORMD is a type of folic acid-conjugated organically modified silica (ORMOSIL) nanoparticle. These dye-loaded nanoparticles are synthesized as targeted optical nanoprobes for in vitro and in vivo imaging. The conjugation of folic acid to the nanoparticle surface facilitates strong cellular uptake in cancer cells that overexpress the folic acid receptor, such as pancreatic cancer Miapaca-2 cells and hepatoma SMMC7721 cells. In vivo studies have demonstrated preferential accumulation of FA-ORMD nanoparticles in tumor sites with low observed toxicity, indicating significant potential for early-cancer detection applications.

Other names: Folic acid-conjugated organically modified silica nanoparticlesFA-conjugated ORMD nanoparticles

Targets

1C metabolism (One-carbon metabolism)

Beyond the preview

Go deeper on FA-ORMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FA-ORMD.

Explore the full profile